InvestorsHub Logo
Followers 36
Posts 5775
Boards Moderated 0
Alias Born 02/20/2015

Re: None

Tuesday, 07/31/2018 7:55:02 PM

Tuesday, July 31, 2018 7:55:02 PM

Post# of 2496
Now that the DSMB has said to conclude the study, CorMedix plans to submit the results of the interim analysis to the FDA for its review. The company will look to add an FDA approval to its CE Mark in Europe that allows Neutrolin to be marketed as a medical device. In post-market studies, Neutrolin was shown to reduce CRBSIs by 96% and blood clots by 96.7% compared to historical benchmarks.


BOOM.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRMD News